- |||||||||| ANT-045 / Antikor Biopharma, ANT-043 / Antikor Biopharma, Herceptin (trastuzumab) / Roche
Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail (Section 21) - Mar 9, 2022 - Abstract #AACR2022AACR_4008;
ANT-045 has excellent in vitro cell-kill potency (pM IC50s) and excellent stability and superior in vivo tumor cure efficacy, compared to a leading clinical stage benchmark ADC. This presentation will focus on Antikor’s FDC discovery platform (stable high-DAR scFv-display libraries, tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumors for patient benefit and promising to succeed where ADCs have failed to deliver.
- |||||||||| ANT-045 / Antikor Biopharma, ANT-043 / Antikor Biopharma
[VIRTUAL] Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_1535;
This presentation will focus on ANT-045’s remarkable development and show that this FDC demonstrates superior efficacy and tolerability compared to an ADC when equated on an equi-mass, equi-molar and equi-payload basis. ANT-045 could be used to switch ‘immunologically-cold’ tumour ‘hot’ to benefit from checkpoint inhibitor therapy and data will be presented to support this concept.
|
